[go: up one dir, main page]

WO2001007087A3 - Enzyme catalyzed anti-infective therapeutic agents - Google Patents

Enzyme catalyzed anti-infective therapeutic agents Download PDF

Info

Publication number
WO2001007087A3
WO2001007087A3 PCT/US2000/019844 US0019844W WO0107087A3 WO 2001007087 A3 WO2001007087 A3 WO 2001007087A3 US 0019844 W US0019844 W US 0019844W WO 0107087 A3 WO0107087 A3 WO 0107087A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
therapeutic agents
infectious agent
enzyme catalyzed
infectious
Prior art date
Application number
PCT/US2000/019844
Other languages
French (fr)
Other versions
WO2001007087A8 (en
WO2001007087A2 (en
Inventor
H Michael Shepard
Original Assignee
Newbiotics Inc
H Michael Shepard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc, H Michael Shepard filed Critical Newbiotics Inc
Priority to AU63589/00A priority Critical patent/AU6358900A/en
Priority to JP2001511970A priority patent/JP2003527317A/en
Priority to MXPA02000761A priority patent/MXPA02000761A/en
Priority to IL14774700A priority patent/IL147747A0/en
Priority to CA002379834A priority patent/CA2379834A1/en
Priority to KR1020027000936A priority patent/KR20020059340A/en
Priority to EP00950490A priority patent/EP1202749A2/en
Publication of WO2001007087A2 publication Critical patent/WO2001007087A2/en
Publication of WO2001007087A8 publication Critical patent/WO2001007087A8/en
Publication of WO2001007087A3 publication Critical patent/WO2001007087A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)

Abstract

This invention provides a method for selectively inhibiting an infectious agent or a cell infected by an infectious agent by contacting the infectious agent or the cell infected with the agent with a prodrug that is selectively converted to a toxin by an activating enzyme expressed by the infectious agent. The activating enzyme is selective for the enzyme expressed by the infectious agent as compared to the same or similar enzyme expressed by the host cell or other infectious agents. The activating agent is not inhibited nor inactivated by the prodrug. Screens for identifying prodrugs are also provided herein.
PCT/US2000/019844 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents WO2001007087A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU63589/00A AU6358900A (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents
JP2001511970A JP2003527317A (en) 1999-07-22 2000-07-21 Enzyme-catalyzed anti-infective therapeutic agent
MXPA02000761A MXPA02000761A (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents.
IL14774700A IL147747A0 (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents
CA002379834A CA2379834A1 (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents
KR1020027000936A KR20020059340A (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents
EP00950490A EP1202749A2 (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14536499P 1999-07-22 1999-07-22
US60/145,364 1999-07-22
US15310199P 1999-09-09 1999-09-09
US60/153,101 1999-09-09

Publications (3)

Publication Number Publication Date
WO2001007087A2 WO2001007087A2 (en) 2001-02-01
WO2001007087A8 WO2001007087A8 (en) 2001-07-12
WO2001007087A3 true WO2001007087A3 (en) 2002-01-17

Family

ID=26842894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019844 WO2001007087A2 (en) 1999-07-22 2000-07-21 Enzyme catalyzed anti-infective therapeutic agents

Country Status (9)

Country Link
EP (1) EP1202749A2 (en)
JP (1) JP2003527317A (en)
KR (1) KR20020059340A (en)
CN (1) CN1391487A (en)
AU (1) AU6358900A (en)
CA (1) CA2379834A1 (en)
IL (1) IL147747A0 (en)
MX (1) MXPA02000761A (en)
WO (1) WO2001007087A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
CA2378187C (en) * 1999-07-22 2011-09-13 Newbiotics, Inc. Methods for treating therapy-resistant tumors
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
AU2001277093A1 (en) * 2000-07-20 2002-02-05 Newbiotics, Inc. Methods for identifying therapeutic targets
US6987180B2 (en) 2002-02-07 2006-01-17 President And Fellows Of Harvard College Uridine analogs and techniques for making and using
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
CN104497083B (en) * 2014-05-12 2017-07-07 河南师范大学 Nucleosides phenylpropen ketone hybrid with Antiparasitic Activity and its preparation method and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012678A2 (en) * 1993-11-05 1995-05-11 Cancer Research Campaign Technology Limited Improvements relating to cancer therapy
WO1999006072A1 (en) * 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2001007088A2 (en) * 1999-07-22 2001-02-01 Newbiotics, Inc. Methods for treating therapy-resistant tumors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012678A2 (en) * 1993-11-05 1995-05-11 Cancer Research Campaign Technology Limited Improvements relating to cancer therapy
WO1999006072A1 (en) * 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2001007088A2 (en) * 1999-07-22 2001-02-01 Newbiotics, Inc. Methods for treating therapy-resistant tumors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAGSHAWE K D: "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY: A REVIEW", DRUG DEVELOPMENT RESEARCH,US,NEW YORK, NY, vol. 34, no. 2, 1 February 1995 (1995-02-01), pages 220 - 230, XP000562092, ISSN: 0272-4391 *
FARROW S N ET AL: "SYNTHESIS AND BIOLOGICAL PROPERTIES OF NOVEL PHOSPHOTRIESTERS A NEW APPROACH TO THE INTRODUCTION OF BIOLOGICALLY ACTIVE NUCLEOTIDES INTO CELLS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 5, 1990, pages 1400 - 1406, XP002171073, ISSN: 0022-2623 *
GRIENGL H ET AL: "PHOSPHONOFORMATE AND PHOSPHONOACETATE DERIVATIVES OF 5-SUBSTITUTED 2'DEOXYURIDINES: SYNTHESIS AND ANTIVIRAL ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 31, no. 9, 1988, pages 1831 - 1839, XP002036743, ISSN: 0022-2623 *
KUMAR A ET AL: "SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME CYCLIC PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 9, 1990, pages 2368 - 2375, XP002171072, ISSN: 0022-2623 *
MCGUIGAN C ET AL: "ARYL PHOSPHORAMIDATE DERIVATIVES OF D4T HAVE IMPROVED ANTI-HIV EFFICACY IN TISSUE CULTURE AND MAY ACT BY THE GENERATION OF A NOVELINTRACELLULAR METABOLITE", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 39, no. 8, 1996, pages 1748 - 1753, XP000578130, ISSN: 0022-2623 *
MELTON ET AL: "Antibody-directed enzyme prodrug therapy (ADEPT). Review article", DRUGS OF THE FUTURE,ES,BARCELONA, vol. 21, no. 2, 1996, pages 167 - 181, XP002080157, ISSN: 0377-8282 *
NICULESCU-DUVAZ I ET AL: "GENE-DIRECTED ENZYME PRODRUG THERAPY: A REVIEW OF ENZYME/PRODRUG COMBINATIONS", EXPERT OPINION ON INVESTIGATIONAL DRUGS,GB,ASHLEY PUBLICATIONS LTD., LONDON, vol. 6, no. 6, 1997, pages 685 - 703, XP000901460, ISSN: 1354-3784 *
WILDNER OLIVER ET AL: "Enzyme prodrug gene therapy: Synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.", CANCER RESEARCH, vol. 59, no. 20, 15 October 1999 (1999-10-15), pages 5233 - 5238, XP001002739, ISSN: 0008-5472 *
WOLFE L A ET AL: "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY WITH THE T268G MUTANT OF HUMAN CARBOXYPEPTIDASE A1: IN VITRO AND IN VIVO STUDIES WITH PRODRUGS OF METHOTREXATE AND THE THYMIDYLATE SYNTHASE INHIBITORS GW1031 AND GW1843", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 10, no. 1, January 1999 (1999-01-01), pages 38 - 48, XP000800838, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
IL147747A0 (en) 2002-08-14
JP2003527317A (en) 2003-09-16
AU6358900A (en) 2001-02-13
CA2379834A1 (en) 2001-02-01
KR20020059340A (en) 2002-07-12
WO2001007087A8 (en) 2001-07-12
EP1202749A2 (en) 2002-05-08
MXPA02000761A (en) 2002-08-12
CN1391487A (en) 2003-01-15
WO2001007087A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
HK1112007A1 (en) Peptide acceptor ligation methods
AU3677900A (en) Agent for improving ketosis
AU2001260559A1 (en) Endoscopic tutorial system for the pancreatic system
AU2001286636A1 (en) Method for assaying the activity of lysosomal enzymes
WO2002100353A3 (en) Cd10-activated prodrug compounds
WO1999057325A3 (en) Enzymes mixture
WO2005042704A3 (en) Differential enzymatic fragmentation
AU4021201A (en) Method for defining an executable business model
WO2000033863A3 (en) Therapeutic agent for the suppression of snoring noises
WO2002059368A8 (en) Specific mucin expression as a marker for pancreatic cancer
WO2001007087A8 (en) Enzyme catalyzed anti-infective therapeutic agents
AU2001249213A1 (en) Graphics system configured to implement fogging based on radial distances
FI20000539L (en) Method for minimizing the impact of interference and radio system
SI1325022T1 (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
DE69909073D1 (en) ACTIVE RELEASE ACTIVATED BY HYDROXYLATION
AU6839300A (en) Nucleic acids which code for the enzyme activities of the spinosyn biosynthesis
WO1999058145A3 (en) Immunomodulators for vaccines
AU7367300A (en) Inactive enzymes as non-consuming sensors
AU2001240656A1 (en) System for producing steel
AU2001277997A1 (en) Diagnostic polymorphisms for the tgf-beta1 promoter
AU2001238407A1 (en) Esterase enzymes having selective activity
HK1046532A1 (en) Phenyl-and pyridyl-tetrahydro-pyridines having tnfinhibiting activity.
AU2001275732A1 (en) Naadp analogues for modulating t-cell activity
AU2001266021A1 (en) Method for producing stable, colorless butadiene rubbers
AU2001264882A1 (en) Watchdog arrangement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 05/2001 UNDER (81) ADD "AG, BZ, CR, DM, DZ, MA, MZ, TZ"

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/000761

Country of ref document: MX

Ref document number: 147747

Country of ref document: IL

Ref document number: 2379834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027000936

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 63589/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000950490

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008130159

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000950490

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027000936

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000950490

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0012669

Country of ref document: BR

Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL, POR TER SIDO A FASE NACIONAL INTEMPESTIVA.